The clinical potential of chemokine receptor antagonists

被引：100

作者：

Ribeiro, S

Horuk, R

机构：

[1] Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA

[2] Berlex Biosci, Dept Mol Pharmacol, Richmond, CA 94804 USA

来源：

PHARMACOLOGY & THERAPEUTICS | 2005年 / 107卷 / 01期

关键词：

chemokine; G-protein coupled receptor; receptor antagonists; autoimmune diseased; multiple sclerosis; clinical trials;

D O I：

10.1016/j.pharmthera.2005.01.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Chemokines belong to a family of chemotactic cytokines that direct the migration of immune cells towards sites of inflammation. They mediate their biological effects by binding to cell surface receptors, which belong to the G protein-coupled receptor superfamily. Since chemokines and their receptors have been implicated in the pathophysiology of a number of autoinflammatory diseases, chemokine receptor antagonists could prove to be useful therapeutics to target these diseases. Here, we review the role of chemokines in autoimmunity, concentrating mainly on the chemokine receptors CCR1 and CCR5, and discuss the potential utility of antagonists that target these 2 receptors as they progress through the clinic. (c) 2005 Published by Elsevier Inc.

引用

页码：44 / 58

页数：15

共 120 条

[1]

ALBERT R, 2002, Patent No. 2002081449

[2]

ALBERT R, 2004, Patent No. 2004031172

[3]

Altman GB, 1999, AM J REPROD IMMUNOL, V42, P168

[4] Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice [J].

Anders, HJ ;

Belemezova, E ;

Eis, V ;

Segerer, S ;

Vielhauer, V ;

De Lema, GP ;

Kretzler, M ;

Cohen, CD ;

Frink, M ;

Horuk, R ;

Hudkins, KL ;

Alpers, CE ;

Mampaso, F ;

Schlöndorff, D .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (06) :1504-1513

[5] A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation [J].

Anders, HJ ;

Vielhauer, V ;

Frink, M ;

Linde, Y ;

Cohen, CD ;

Blattner, SM ;

Kretzler, M ;

Strutz, F ;

Mack, M ;

Gröne, HJ ;

Onuffer, J ;

Horuk, R ;

Nelson, PJ ;

Schlöndorff, D .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (02) :251-259

[6]

Anderson K, 1999, SEMIN ONCOL, V26, P10

[7]

Anderson Kenneth C, 2002, Hematology Am Soc Hematol Educ Program, P214

[8]

ANORMED INC, 2002, Patent No. [00222599, 0222599]

[9] Analysis of the involvement of CCR5-Δ32 and CCR2-V64I variants in the development of endometriosis [J].

Antiñolo, G ;

Fernández, RM ;

Noval, JA ;

Moliní, JL ;

Borrego, S .

MOLECULAR HUMAN REPRODUCTION, 2004, 10 (03) :155-157

[10] T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure [J].

Arakaki, R ;

Tamamura, H ;

Premanathan, M ;

Kanbara, K ;

Ramanan, S ;

Mochizuki, K ;

Baba, M ;

Fujii, N ;

Nakashima, H .

JOURNAL OF VIROLOGY, 1999, 73 (02) :1719-1723

← 1 2 3 4 5 6 7 8 9 10 →